Reno 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Orbit pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particulary obstetric patients
Pharmacology
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
Dosage varies for different conditions. For duodenal and gastric ulcer, the usual dosage is 150 mg twice daily taken in the morning and evening or 300 mg as a single daily dose at night for 4 to 8 weeks. For reflux oesophagitis, the dosage is 150 mg twice daily or 300 mg at bed time for up to 8 weeks. The dosage for Zollinger Ellison syndrome is 150 mg 3 times daily and increased if necessary up to 6 g daily in divided doses. It also includes administration details for IV injection & IV infusion and recommended oral dose for children.
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. It may alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide) and reduce bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Pregnancy: Ranitidine crosses the placenta. But there is no evidence of impaired fertility or harm to the fetus due to Ranitidine. Ranitidine should only be used during pregnancy if considered essential.
- Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when the drug is administered to a nursing mother.
Precautions & Warnings
Reno should be given in reduced dosage to patients with impaired renal and hepatic function.
Use in Special Populations
In clinical trial the ulcer healing rates have been found similar in elderly patients with those in younger patients. Additionally, there was no difference in the incidence of adverse effects.
Overdose Effects
Reno is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodialysis.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Slow IV inj: Reno 50 mg diluted to a concentration ≤2.5 mg/mL with NaCl 0.9% inj or dextrose 5% or 10%, lactated Ringer's, Na bicarbonate 5% solution.
- Intermittent slow IV infusion: Reno 50 mg diluted to a concentration ≤0.5 mg/mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution.
- Continuous IV infusion: Reno 150 mg diluted in 250 mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution.
- Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Reno should be diluted to a concentration ≤2.5 mg/mL with dextrose 5% or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution.
Storage Conditions
Store in a cool and dry place. Protect from light.